The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Protein concentration is above or equal to 0.05 mg/ml.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped on dry ice. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.
pH: 8.00 Constituents: 0.31% Glutathione, 0.79% Tris HCl
acyl CoA synthetase 4
Acyl CoA synthetase long chain family member 4
Fatty acid Coenzyme A ligase
fatty acid Coenzyme A ligase long-chain 4
Lignoceroyl CoA synthase
Long chain 4
long chain acyl CoA synthetase 4
long chain fatty acid CoA ligase 4
long chain fatty acid Coenzyme A ligase 4
Long-chain acyl-CoA synthetase 4
Long-chain-fatty-acid--CoA ligase 4
Activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially uses arachidonate and eicosapentaenoate as substrates.
Involvement in disease
Defects in ACSL4 are the cause of mental retardation X-linked type 63 (MRX63) [MIM:300387]. Mental retardation is a mental disorder characterized by significantly sub-average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period. Non-syndromic mental retardation patients do not manifest other clinical signs. Defects in ACSL4 are involved in Alport syndrome with mental retardation midface hypoplasia and elliptocytosis (ATS-MR) [MIM:300194]. A X-linked contiguous gene deletion syndrome characterized by glomerulonephritis, deafness, mental retardation, midface hypoplasia and elliptocytosis.
Belongs to the ATP-dependent AMP-binding enzyme family.